TimesSquare Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

TimesSquare Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-625,500	Closed	-$56.2M	–	244
2020 Q1	$56.2M	Buy	+625,500	New	+$61.4M	0.67%	48
2017 Q2	–	Sell	-34,240	Closed	-$4.15M	–	267
2017 Q1	$4.15M	Sell	34,240 -595	-2%	-$76.7K	0.03%	238
2016 Q4	$4.26M	Buy	34,835 +5,895	+20%	+$721K	0.03%	232
2016 Q3	$3.55M	Sell	28,940 -925	-3%	-$119K	0.02%	237
2016 Q2	$3.49M	Sell	29,865 -9,690	-24%	-$1.37M	0.02%	228
2016 Q1	$5.51M	Buy	39,555 +32,095	+430%	+$4.71M	0.04%	223
2015 Q4	$1.42M	Buy	+7,460	New	+$1.3M	0.01%	238

Other funds holding ALXN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TimesSquare Capital Management's ALXN Position: Q2 2020 in Review

TimesSquare Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 625,500 shares — an estimated $56.2M sold.

TimesSquare Capital Management first reported a position in ALXN in Q4 2015 and held it in 7 quarters. The position peaked at $56.2M in Q1 2020. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

TimesSquare Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
TimesSquare Capital Management sold 625,500 Alexion Pharmaceuticals shares in Q2 2020, an estimated $56.2M.
TimesSquare Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 7 quarters.
TimesSquare Capital Management's Alexion Pharmaceuticals position peaked at $56.2M in Q1 2020.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on TimesSquare Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.